MY209568A - Fimh mutant, compositions therewith and use thereof - Google Patents

Fimh mutant, compositions therewith and use thereof

Info

Publication number
MY209568A
MY209568A MYPI2022003755A MYPI2022003755A MY209568A MY 209568 A MY209568 A MY 209568A MY PI2022003755 A MYPI2022003755 A MY PI2022003755A MY PI2022003755 A MYPI2022003755 A MY PI2022003755A MY 209568 A MY209568 A MY 209568A
Authority
MY
Malaysia
Prior art keywords
fimh
compositions therewith
polypeptides
mutant
lectin domain
Prior art date
Application number
MYPI2022003755A
Other languages
English (en)
Inventor
Jan Grijpstra
Louris Jakob Feitsma
Eveline Marleen Weerdenburg
Jeroen Geurtsen
Kellen Cristhina Fae
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of MY209568A publication Critical patent/MY209568A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MYPI2022003755A 2020-01-16 2021-01-14 Fimh mutant, compositions therewith and use thereof MY209568A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20152217 2020-01-16
PCT/EP2021/050707 WO2021144369A1 (en) 2020-01-16 2021-01-14 Fimh mutant, compositions therewith and use thereof

Publications (1)

Publication Number Publication Date
MY209568A true MY209568A (en) 2025-07-22

Family

ID=69174406

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2022003755A MY209568A (en) 2020-01-16 2021-01-14 Fimh mutant, compositions therewith and use thereof

Country Status (25)

Country Link
US (3) US11421003B2 (enExample)
EP (2) EP4090363B1 (enExample)
JP (2) JP7485771B2 (enExample)
KR (1) KR20220128372A (enExample)
CN (1) CN115038461A (enExample)
AR (1) AR121066A1 (enExample)
AU (1) AU2021208493B2 (enExample)
BR (1) BR112022013720A2 (enExample)
CA (1) CA3168108A1 (enExample)
DK (1) DK4090363T3 (enExample)
ES (1) ES2987890T3 (enExample)
FI (1) FI4090363T3 (enExample)
HR (1) HRP20241370T1 (enExample)
HU (1) HUE068985T2 (enExample)
IL (1) IL294445B2 (enExample)
LT (1) LT4090363T (enExample)
MX (1) MX2022008830A (enExample)
MY (1) MY209568A (enExample)
PL (1) PL4090363T3 (enExample)
PT (1) PT4090363T (enExample)
RS (1) RS66031B1 (enExample)
SA (1) SA522433319B1 (enExample)
SI (1) SI4090363T1 (enExample)
TW (1) TWI868297B (enExample)
WO (1) WO2021144369A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
ES2987890T3 (es) 2020-01-16 2024-11-18 Janssen Pharmaceuticals Inc Mutante de FimH, composiciones con el mismo y uso del mismo
CN115605498A (zh) 2020-02-23 2023-01-13 辉瑞公司（Us） 大肠杆菌组合物及其方法
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
KR102746713B1 (ko) 2021-01-12 2024-12-24 얀센 파마슈티칼즈, 인코포레이티드 FimH 돌연변이체, 이를 포함하는 조성물 및 이의 용도
JP2025503423A (ja) * 2021-12-17 2025-02-04 ファイザー・インク ポリヌクレオチド組成物およびその使用
EP4531902A1 (en) 2022-05-25 2025-04-09 CureVac SE Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
JP7656656B2 (ja) * 2022-06-20 2025-04-03 ファイザー・インク 大腸菌ＦｉｍＨ変異体およびその使用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
JPH0655749B2 (ja) 1989-09-20 1994-07-27 日本たばこ産業株式会社 リピッドａ単糖類縁体
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
US5593969A (en) 1991-09-03 1997-01-14 Igen Incorporated Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
PL190237B1 (pl) 1997-04-01 2005-11-30 Corixa Corp Kompozycja adiuwantowa, szczepionka, sposób wytwarzania kompozycji adiuwantowej oraz zastosowanie
US6500434B1 (en) 1998-04-23 2002-12-31 Medimmune, Inc. Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
CN101926993B (zh) 1998-10-16 2013-12-04 史密丝克莱恩比彻姆生物有限公司 佐剂系统及疫苗
AU1431101A (en) 1999-10-04 2001-05-10 University Of Maryland Biotechnology Institute Novel adjuvant comprising a lipopolysaccharide antagonist
ES2309064T3 (es) 2000-04-13 2008-12-16 Corixa Corporation Composiciones inmunoestimulantes que comprenden un fosfato de aminoalquil glucosaminida y qs-21.
WO2002004496A2 (en) 2000-07-07 2002-01-17 Medimmune, Inc. Fimh adhesin proteins and methods of use
EP1313502A4 (en) 2000-08-18 2005-10-19 Medimmune Inc ADMINISTRATIVE PROCEDURE OF FIMH PROTEIN AS A VACCINE AGAINST HARNWAY INFECTIONS
US20030199071A1 (en) 2000-12-08 2003-10-23 Solomon Langermann Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
CN101355928B (zh) 2005-04-26 2013-05-22 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
KR101524636B1 (ko) 2005-05-11 2015-06-03 에테하 취리히 원핵 세포로부터의 재조합 ｎ-글리코실화 단백질
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
WO2007109812A2 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
US8895014B2 (en) 2008-02-20 2014-11-25 Glycovaxyn Ag Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells
PT2437753T (pt) 2009-06-05 2016-11-23 Infectious Disease Res Inst Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
RS58868B1 (sr) 2012-02-07 2019-08-30 Infectious Disease Res Inst Poboljšane adjuvansne formulacije koje sadrže agoniste tlr4 i postupci upotrebe istih
SI2996473T1 (sl) 2013-05-18 2019-12-31 Aduro Biotech, Inc. Sestavki in postopki za aktiviranje signaliziranja, odvisnega od "stimulator interferonskih genov"
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) * 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9415101B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9415097B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
PL3110441T3 (pl) 2014-02-24 2024-08-05 Glaxosmithkline Biologicals S.A. Nowatorski polisacharyd i jego zastosowania
WO2016183501A1 (en) * 2015-05-13 2016-11-17 University Of Washington Compositions and methods for treatment and prevention of uropathogenic e. coli infection
EP3319633B1 (en) 2015-07-07 2020-11-11 Janssen Vaccines & Prevention B.V. Vaccine against rsv
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
WO2019175145A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against urinary tract infections
EP4077372A1 (en) 2019-12-20 2022-10-26 Vib Vzw Nanobody exchange chromatography
ES2987890T3 (es) 2020-01-16 2024-11-18 Janssen Pharmaceuticals Inc Mutante de FimH, composiciones con el mismo y uso del mismo
KR102746713B1 (ko) 2021-01-12 2024-12-24 얀센 파마슈티칼즈, 인코포레이티드 FimH 돌연변이체, 이를 포함하는 조성물 및 이의 용도

Also Published As

Publication number Publication date
RS66031B1 (sr) 2024-11-29
TW202140521A (zh) 2021-11-01
LT4090363T (lt) 2024-09-25
US12428449B2 (en) 2025-09-30
DK4090363T3 (da) 2024-09-30
IL294445A (en) 2022-09-01
MX2022008830A (es) 2022-10-07
JP7485771B2 (ja) 2024-05-16
SA522433319B1 (ar) 2024-07-10
KR20220128372A (ko) 2022-09-20
JP2024045126A (ja) 2024-04-02
US11421003B2 (en) 2022-08-23
IL294445B1 (en) 2023-06-01
AU2021208493B2 (en) 2023-03-30
US20230049056A1 (en) 2023-02-16
JP2023500749A (ja) 2023-01-10
AU2021208493A1 (en) 2022-06-30
EP4461744A2 (en) 2024-11-13
HUE068985T2 (hu) 2025-02-28
HRP20241370T1 (hr) 2024-12-20
AR121066A1 (es) 2022-04-13
CN115038461A (zh) 2022-09-09
US12012435B2 (en) 2024-06-18
ES2987890T3 (es) 2024-11-18
PT4090363T (pt) 2024-09-19
FI4090363T3 (fi) 2024-09-25
PL4090363T3 (pl) 2024-11-25
US20240294582A1 (en) 2024-09-05
IL294445B2 (en) 2023-10-01
EP4090363A1 (en) 2022-11-23
EP4461744A3 (en) 2025-01-08
BR112022013720A2 (pt) 2022-10-11
WO2021144369A1 (en) 2021-07-22
CA3168108A1 (en) 2021-07-22
US20210221856A1 (en) 2021-07-22
SI4090363T1 (sl) 2024-10-30
EP4090363B1 (en) 2024-09-04
TWI868297B (zh) 2025-01-01

Similar Documents

Publication Publication Date Title
MY209568A (en) Fimh mutant, compositions therewith and use thereof
MX2021004056A (es) Cepa de akkermansia muciniphila y uso de la misma.
MX2025003080A (es) Conjugados de il-15, y sus usos
MX2021005092A (es) Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden.
MY193353A (en) Anti-vegf protein compositions and methods for producing the same
MX2022000369A (es) Cepa bacteriana de bifidobacterium bifidum, las composiciones de la misma y usos relacionados.
MX2018001567A (es) Novedosos polipeptidos de fusion especificos para lag-3 y pd-1.
NZ770137A (en) Lactobacillus gasseri kbl697 strain and use thereof
MX2019007144A (es) Nuevos agonistas de tnfr y sus usos.
MX2023008251A (es) Mutantes de fimh, composiciones con estos y uso de estos.
HRP20231437T1 (hr) Il-15 i il-15ralpha sushi domena na temelju modulokina
WO2020076136A3 (ko) 아커만시아 뮤시니필라 균주 및 이의 용도
MA45172B1 (fr) Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
MX2023008191A (es) Productos bioterapéuticos hipoinmunogénicos.
MX2023003230A (es) Procesos e intermediario para la preparacion a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbon il)-piridin-2-il]-benzamida y preparacion de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il ]-benzamida.
MY205028A (en) Protein for treatment of inflammatory diseases
de Melo et al. Immunomodulatory response of Cramoll 1, 4 lectin on experimental lymphocytes
Zabłocka et al. Colostral proline-rich polypeptide complexes. Comparative study of the antioxidant properties, cytokine-inducing activity, and nitric oxide release of preparations produced by a laboratory and a large-scale method
Imatani et al. Histatin 5 inhibits inflammatory cytokine induction from human gingival fibroblasts by Porphyromonas gingivalis
Munblit et al. Modulating breast milk composition-the key to allergy prevention?
MY173078A (en) Tgf?-derived polypeptides and uses thereof
MX2020006294A (es) Composiciones de vacunas y método para elaborarlas.
Seneviratne et al. Identification of antifungal molecules from novel probiotic Lactobacillus bacteria for control of Candida infection
Kuan et al. Molecular cloning of a new immunomodulatory protein from Anoectochilus formosanus which induces B cell IgM secretion through a T-independent mechanism
Ikhsas et al. The Effect of Pomegranate Peel (Punica granatum L.) Extract in Chitosan Nanoparticle on the Macrophage Polarization in DSS-Induced Mice.